C.E.R.A. (Continuous Erythropoietin Receptor Activator): A new perspective in anaemia management

Continuous Erythropoietin Receptor Activator(C.E.R.A.), an innovative agent with unique receptor activity and a prolonged half-life, is currently in development to provide correction of anaemia and stable control of haemoglobin (Hb) levels at extended administration intervals in patients with chronic kidney disease (CKD) on dialysis and not on dialysis. Phase II studies suggest that C.E.R.A. can correct anaemia and maintain Hb levels when administered intravenously or subcutaneously at extended intervals of up to once monthly. C.E.R.A. is currently undergoing evaluation for the control of anaemia in patients with CKD in a large-scale Phase III programme.